Europe
Oxurion NV launches new global website showcasing its comprehensive drug development approach and diverse portfolio of next-generation therapies for back of the eye disease
Lunaphore Technologies SA and A. Menarini Diagnostics S.r.l. today jointly announce the start of a strategic partnership bringing to the market a new and innovative system, using Lunaphore’s technology.
Days after receiving a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Nucala (mepolizumab) as an add-on COPD treatment, GlaxoSmithKline released data that showed the same medication was a superior treatment in severe eosinophilic asthma in patients with similar blood eosinophil counts.
Positive Topline Results for Diabetic Eye Disease Portfolio
Medigene AG announces that the Medigene share will be part of the SDAX from 24 September 2018 onwards, following the restructuring of the Deutsche Börse indices.
LEUKOCARE AG and Xellia Pharmaceuticals, have entered into a global strategic partnership, where both companies will collaborate closely to discover innovative and superior formulations to support the development of Xellia’s pipeline of value-added antibiotic and antifungal products which are intended to enhance patient care.
Polyphor AG today announced its financial results for the first half of 2018.
Polyphor and Novo Holdings A / S announced today that got Polyphor CHF 6.8 million in new capital from Novo REPAIR Impact Fund to promote the development of novel antibiotics directed against proteins of the outer cell membrane.
BioChaperone® Pramlintide Insulin (BC Pram Ins) is the first product to clinically demonstrate the feasibility of a fixed-ratio co-formulation of pramlintide and human insulin
Inoviem Scientific today announces a service-based partnership with XoNovo, a preclinical-stage biopharmaceutical company developing a proprietary small molecule for the treatment of neurodegenerative diseases. Financial terms of the partnership were not disclosed.
PRESS RELEASES